A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant T
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
| Condition(s) | Resectable Lung Non-Small Cell Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy. |
| Who can participate | Inclusion Criteria: * Resectable NSQ NSCLC * Age 18-65 years * male or female * ECOG 0-1 * Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer * Subjects must have adequate pulmonary function for the intended pneumonectomy; Exclusion Criteria: * SCLC or SQ NSCLC * previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc. * patients who have previously used anti-angiogenic drugs; * allergic to any component of the study drug or chemotherapy drugs * patients with any severe and or uncontrolled disease |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Locations | Guangzhou, China |
| Start date | 2024-09-24 |
| NCT ID | NCT06775275 |
| Official listing | https://clinicaltrials.gov/study/NCT06775275 |